生物製藥第三方物流(3PL) 市場規模、佔有率和成長分析（按供應鏈、服務類型和地區分類）－產業預測 (2026-2033)

全球生物製藥第三方物流(3PL) 市場規模預計到 2024 年將達到 1324.1 億美元，到 2025 年將達到 1404.9 億美元，到 2033 年將達到 2256.1 億美元，預測期（2026-2033 年）的複合年成長率為 6.1%。

隨著製藥公司擴大將物流服務外包以更有效率地管理其分銷網路，生物製藥第三方物流(3PL) 市場正經歷顯著成長。 3PL 服務商透過先進的倉庫管理系統，簡化小分子藥物的收貨、訂單履行和庫存管理流程，從而為製藥公司和醫療機構提供支援。這不僅降低了營運成本，防止產品供應中斷，還有助於提高整體組織效率。推動市場成長的因素包括：強勁的銷售業績促使企業更加重視物流最佳化；生物相似藥上市數量不斷增加；以及對溫控包裝創新技術的需求，尤其是在疫情期間供應鏈中斷之後。整體而言，生物製藥 3PL 市場前景良好。

全球生物製藥第三者物流(3PL) 市場促進因素

對安全運輸溫控藥品的高效物流解決方案的需求不斷成長，預計將顯著推動生物物流第三方物流 (3PL) 市場的發展。生物製藥和生物相似藥的擴張是推動市場成長的主要因素，因為這些藥物的配送需要溫控物流服務。此外，為降低營運成本，生產設施自動化程度的不斷提高也進一步刺激了對 3PL 服務的需求。同時，慢性病盛行率的上升也導致生物製藥需求增加，加速了生物製藥第三方物流市場的擴張。

全球生物製藥第三者物流(3PL) 市場限制因素

全球生物製藥第三方物流(3PL) 市場面臨嚴峻挑戰，新興經濟體物流服務發展速度遠落後於已開發地區。這種服務發展差距部分源自於生物製藥 3PL 領域熟練勞動力短缺。合格人才的匱乏阻礙了該行業滿足日益成長的物流服務需求並實現成長的能力。因此，勞動力短缺嚴重限制了全球醫藥 3PL 市場的擴張和效率，最終影響整個生物製藥產業的供應鏈和服務交付。

全球生物製藥第三方物流（3PL）市場趨勢

全球生物製藥第三方物流(3PL) 市場的一大趨勢是向先進物流解決方案轉型，這主要受附加價值服務需求成長的驅動。各公司正加大研發投入以提升自身能力，例如透過整合智慧感測器技術來監測運輸過程中的環境狀況。這項創新改進了敏感生物製藥產品的追蹤和處理，確保合規性和安全性。 DHL 等物流供應商正利用這些技術進步來最佳化其配送網路，並在一個優先考慮效率、可靠性和合規性的市場中獲得競爭優勢。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球生物製藥第三方物流(3PL) 市場規模（按供應鏈和複合年成長率分類）（2026-2033 年）

• 低溫運輸物流
• 非低溫運輸物流

全球生物製藥第三方物流(3PL) 市場規模（按服務類型和複合年成長率分類）（2026-2033 年）

• 運輸
  • 空運貨物
  • 海上運輸
  • 陸運
• 倉儲和存儲
• 其他服務

全球生物製藥第三方物流(3PL) 市場規模及複合年成長率 (2026-2033)

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• DHL（Germany）
• FedEx（USA）
• United Parcel Service（UPS）（USA）
• Kuehne+Nagel（Switzerland）
• DB Schenker（Germany）
• Agility（Kuwait）
• AmerisourceBergen Corporation（USA）
• McKesson Corporation（USA）
• Cardinal Health（USA）
• Thermo Fisher Scientific（USA）
• Cencora, Inc.（USA）
• EVERSANA（USA）
• Kerry Logistics Network Limited（Hong Kong）
• SF Express（China）
• XPO Logistics（USA）
• CEVA Logistics（Switzerland）
• Almac Group（UK）
• Cryoport, Inc.（USA）

結論與建議

Global Biopharmaceuticals Third Party Logistics 3pl Market size was valued at USD 132.41 Billion in 2024 and is poised to grow from USD 140.49 Billion in 2025 to USD 225.61 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).

The market for biopharmaceutical third-party logistics (3PL) is experiencing significant growth due to the increasing trend of pharmaceutical companies outsourcing logistics services to handle their distribution networks more efficiently. 3PL providers support pharmaceutical and medical organizations by streamlining the receiving of small molecule pharmaceuticals, fulfilling orders, and managing inventory through advanced warehouse management systems. This not only helps reduce overhead costs and ensures an uninterrupted product supply but also enhances overall organizational efficiency. Factors driving market growth include a heightened focus on optimizing logistics amidst strong sales performances, the rise in biosimilar launches, and the need for innovations in temperature-controlled packaging, particularly following supply chain disruptions experienced during the pandemic. Overall, the biopharmaceutical 3PL market demonstrates a robust outlook.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals Third Party Logistics 3pl market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Third Party Logistics 3pl Market Segments Analysis

Global Biopharmaceuticals Third Party Logistics 3pl Market is segmented by Supply Chain, Service Type and region. Based on Supply Chain, the market is segmented into Cold Chain Logistics and Non-cold Chain Logistics. Based on Service Type, the market is segmented into Transportation, Warehousing and Storage and Other Services. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biopharmaceuticals Third Party Logistics 3pl Market

The increasing need for efficient logistics solutions to safely transport temperature-sensitive medications is anticipated to significantly boost the biopharmaceutical third-party logistics (3PL) market. The expansion of biologics and biosimilars, which necessitate temperature-controlled logistics services for distribution, is a major contributor to this market's growth. Additionally, the rising implementation of automation in manufacturing facilities aims to lower operational costs and is further driving the demand for 3PL services. Moreover, the growing prevalence of chronic illnesses has led to a heightened requirement for biologics, which in turn accelerates the expansion of the biopharmaceutical third-party logistics market.

Restraints in the Global Biopharmaceuticals Third Party Logistics 3pl Market

The global biopharmaceutical third-party logistics (3PL) market faces significant challenges due to the slower development of logistics services in emerging economies compared to those in developed regions. This disparity in service advancement is partly driven by a scarcity of skilled labor within the biopharmaceutical 3PL sector. The lack of qualified professionals hinders the industry's ability to grow and adapt to the increasing demand for logistics services. Consequently, these workforce limitations pose a considerable restraint on the expansion and efficiency of the global pharmaceutical 3PL market, ultimately affecting the overall supply chain and service delivery within the biopharmaceutical industry.

Market Trends of the Global Biopharmaceuticals Third Party Logistics 3pl Market

The Global Biopharmaceuticals Third Party Logistics (3PL) market is witnessing a significant trend towards advanced logistical solutions driven by escalating demand for value-added services. Companies are increasingly investing in research and development to enhance their capabilities, particularly through the integration of smart sensor technology that monitors ambient conditions during transportation. This innovation allows for improved tracking and handling of sensitive biopharmaceutical products, thereby ensuring compliance and safety. Logistics providers like DHL are leveraging these technological advancements to optimize their distribution networks, positioning themselves competitively in a market that emphasizes efficiency, reliability, and regulatory adherence.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Biopharmaceuticals Third Party Logistics 3pl Market Size by Supply Chain & CAGR (2026-2033)

• Market Overview
• Cold Chain Logistics
• Non-cold Chain Logistics

Global Biopharmaceuticals Third Party Logistics 3pl Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Transportation
  • Air Freight
  • Sea Freight
  • Overland
• Warehousing and Storage
• Other Services

Global Biopharmaceuticals Third Party Logistics 3pl Market Size & CAGR (2026-2033)

• North America (Supply Chain, Service Type)
  • US
  • Canada
• Europe (Supply Chain, Service Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Supply Chain, Service Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Supply Chain, Service Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Supply Chain, Service Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• DHL (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FedEx (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Parcel Service (UPS) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kuehne+Nagel (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DB Schenker (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agility (Kuwait)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AmerisourceBergen Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• McKesson Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cencora, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EVERSANA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kerry Logistics Network Limited (Hong Kong)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SF Express (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• XPO Logistics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CEVA Logistics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cryoport, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations